|
Market Closed -
Nasdaq
00:00:00 14/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 22.83 USD | -4.99% |
|
-13.56% | -17.64% |
| 11-10 | Wedbush Raises Price Target on Beam Therapeutics to $33 From $30, Keeps Outperform Rating | MT |
| 11-10 | Beam Therapeutics Says Risto-Cel Meets Primary Endpoints in Sickle Cell Disease Trial | MT |
Company Valuation: Beam Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,327 | 2,692 | 2,159 | 1,974 | 2,736 | 2,275 | - | - |
| Change | - | -49.47% | -19.78% | -8.58% | 38.6% | -16.83% | - | - |
| Enterprise Value (EV) 1 | 4,367 | 1,613 | 969.4 | 1,974 | 2,441 | 1,385 | 1,893 | 1,679 |
| Change | - | -63.05% | -39.92% | 103.62% | 23.66% | -43.25% | 36.66% | -11.31% |
| P/E | -13.8x | -9.47x | -15.8x | -5.41x | -34.2x | -4.95x | -4.4x | -4.52x |
| PBR | 6.19x | 3.66x | 2.14x | 2.83x | 2.28x | 2.85x | 6.76x | 4.29x |
| PEG | - | 0.3x | 0.3x | -0x | 0.4x | -0x | -0.4x | 1.68x |
| Capitalization / Revenue | 103x | 44.2x | 5.72x | 31.1x | 19.6x | 59.1x | 72.9x | 35.5x |
| EV / Revenue | 84.2x | 26.5x | 2.57x | 31.1x | 17.5x | 36x | 60.6x | 26.2x |
| EV / EBITDA | -11.3x | -4.97x | -6.2x | -5.01x | -6.75x | -2.81x | -3.32x | -2.97x |
| EV / EBIT | -11.1x | -4.77x | -5.49x | -4.75x | -6.36x | -2.7x | -3.23x | -2.73x |
| EV / FCF | -38.6x | -61.1x | -5.3x | -5.54x | -6.78x | -3.04x | -3.96x | -3.32x |
| FCF Yield | -2.59% | -1.64% | -18.9% | -18% | -14.8% | -32.8% | -25.3% | -30.1% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -5.77 | -4.13 | -1.72 | -4.58 | -0.81 | -4.615 | -5.192 | -5.053 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 51.84 | 60.92 | 377.7 | 63.52 | 139.7 | 38.51 | 31.22 | 64.1 |
| EBITDA 1 | -385 | -324.3 | -156.5 | -393.6 | -361.4 | -492.2 | -570.6 | -565.3 |
| EBIT 1 | -392.5 | -338.5 | -176.5 | -415.6 | -383.7 | -513.2 | -585.7 | -614.3 |
| Net income 1 | -370.6 | -289.1 | -132.5 | -376.7 | -79.99 | -480.5 | -561.1 | -583 |
| Net Debt 1 | -960.4 | -1,078 | -1,190 | - | -294.9 | -890.2 | -382.4 | -596.4 |
| Reference price 2 | 79.69 | 39.11 | 27.22 | 24.80 | 27.72 | 22.83 | 22.83 | 22.83 |
| Nbr of stocks (in thousands) | 66,849 | 68,821 | 79,326 | 79,592 | 98,693 | 99,670 | - | - |
| Announcement Date | 2/28/22 A | 2/28/23 A | 2/27/24 A | 2/25/25 A | 2/24/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.95x | 35.97x | -2.81x | -.--% | 2.28B | |
| 17.35x | 6.64x | 12.72x | 1.72% | 66.33B | |
| 32.78x | 8.77x | 28.98x | 0.07% | 60.62B | |
| 38.6x | 6.87x | 20.53x | 0.84% | 55.5B | |
| 44.7x | 6.26x | 29.77x | -.--% | 47.58B | |
| 34.6x | 3.29x | 14.2x | -.--% | 43.69B | |
| -20.57x | 54.42x | -22.49x | -.--% | 37.27B | |
| 36.15x | 8.94x | 23.31x | 0.36% | 36.57B | |
| 40.59x | 7.89x | 26.33x | -.--% | 32.22B | |
| -73.93x | 14x | -75.29x | -.--% | 26.58B | |
| Average | 14.53x | 15.31x | 5.53x | 0.3% | 41B | |
| Weighted average by Cap. | 21.55x | 11.89x | 11.34x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- BEAM Stock
- Valuation Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
